(NYSE: RCUS) Arcus Biosciences's forecast annual revenue growth rate of -1.2% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.39%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.86%.
Arcus Biosciences's revenue in 2024 is $247,000,000.On average, 4 Wall Street analysts forecast RCUS's revenue for 2024 to be $22,662,592,802, with the lowest RCUS revenue forecast at $22,308,311,220, and the highest RCUS revenue forecast at $23,085,445,013. On average, 4 Wall Street analysts forecast RCUS's revenue for 2025 to be $9,619,819,221, with the lowest RCUS revenue forecast at $2,742,825,150, and the highest RCUS revenue forecast at $14,342,689,847.
In 2026, RCUS is forecast to generate $26,823,549,982 in revenue, with the lowest revenue forecast at $9,142,750,500 and the highest revenue forecast at $47,085,165,075.